Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 236-270

  Shalinsky, D R ^a   Brekken, J ^a   Zou, H ^a   McDermott, C D ^a   Forsyth, P ^b   Edwards, D ^b   Margosiak, S ^a   Bender, S ^a   Truitt, G ^c   Wood, A ^c   Varki, N M ^d   Appelt, K ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PRINOMASTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST TUMOR; CANCER INHIBITION; CELL PROLIFERATION; COLON TUMOR; CONFERENCE PAPER; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERABILITY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG TUMOR; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE TUMOR; STOMACH TUMOR; TUMOR GROWTH; TUMOR MODEL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0032837028     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07689.x     Document Type: Conference Paper

References (72)

1. 1. Ruddon, W.R. 1955. Characteristics of human cancer. In Cancer Biology, 3rd ed.: 3-18. Oxford University Press. New York.
2. 2. Trichopoulos, D., L. Lipworth, E. Petridou & H-O. Adami. 1997. Epidemiology of cancer. In Cancer: Principles and Practice of Oncology, 5th ed. V.T. DeVita, S. Hellman & S.A. Rosenberg, Eds. J.B. Lippincott. Philadelphia.
3. 3. Bunn, Jr., P.A. & K. Kelly. 1998. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 5: 1087-1100.
4. 4. Shepherd, F.A. 1997. Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Lung Cancer 17 (Suppl. 1): 121-136.
5. 5. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285: 1182-1186.
6. 6. Kerbel, R.S. 1991. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer agents. BioEssays 13: 31-36.
7. 7. Levy, D.E. & A.M. Ezrin. 1997. Matrix metalloproteinase inhibitor drugs. In Emerging Drugs: The Prospective for Improved Medicines. Ashley Publications Ltd.
8. 8. Wojtowicz-Praga, S.M., R.B. Dickson & M. Hawkins. 1997. Matrix metalloproteinase inhibitors. Invest. New Drugs 15: 61-75.
9. 9. Morphy, J.R., T.A. Millican & J.R. Porter. 1995. Matrix metalloproteinase inhibitors: current status. Cur. Med. Chem. 2: 743-762.
10. 10. Ray, J.M, & W.G. Stetler-Stevenson. 1996. Matrix metalloproteinases and malignant disease: recent developments. Exp. Opin. Invest. Drugs 5: 323-335.
11. 11. Brown, P.D. 1997. Matrix metalloproteinase inhibitors in the treatment of cancer. Med. Oncol. 14: 1-10.
12. 12. Liotta, L.A., K. Tryggvason, W.G.I. Moor & M.K. Bodden. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68.
13. 13. Fidler, I. 1997. Molecular biology of cancer: invasion and metastasis In Cancer: Principles and Practice of Oncology, 5th ed. V.T. DeVita, S. Hellman, & S.A. Rosenberg, Eds. J.B. Lippincolt. Philadelphia.
14. 14. Brooks, P.C., S. Stromblad, L.C. Sanders, T.L. Von Schalsch, R.T. Aimes, W.G. Stetler-Stevenson, J.P. Quigley & D.A. Cheresh. 1996. Localization of matrix metalloproteinase MMP-2 on the surface of invasive cells by interaction with integrin αvβ3. Cell 85: 683-693.
15. 15. Varner, J, & D. Cheresh. 1997. Tumor angiogenesis and the role of vascular cell integrin αvβ3. In Importance Advances in Oncology. V. DeVita, S. Hellman & S.A. Rosenberg, Eds. Lippincott-Raven. Philadelphia.
16. 16. Itoh, T., M. Tanioka, H. Yoshida, T. Yohsioka, H. Nishimoto & S. Itohara. 1998. Reduced angiogenesis and tumor progression in gelatinase-A deficient mice. Cancer Res. 58: 1048-1051.
17. 17. Sato, H., T. Takino, Y. Okada, J. Cao, A. Shinagawa, E. Yamamoto &M. Seiki. 1994. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65.
18. 18. Strongin, A.Y., I. Collier, G. Bannikov, B.L. Marmer, G.A. Grant & G.I. Goldberg. 1995. Mechanism of cell surface activation of 72-kDA type IV collagenase. J. Biol. Chem. 270: 5331-5338.
19. 19. Nagase, H. 1998. Stromelysins 1 and 2. In Matrix Metalloproteinases. W.C. Parks & R.P. Mecham, Eds.: 43-68. Academic Press. San Diego, CA.
20. 20. Edwards, D.R., P.P. Beaudry, T.D. Laing, V. Kowal, K.J. Leco & M.S. Lim. 1996. The role of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth. Int. J. Obesity 20: S9-S15.
21. 21. Nakagawa, T., T. Kubota, M. Kabuto, K. Sato, H. Kawano, T. Hayakawa & T. Okada. 1994. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 by human brain tumors. J. Neurosurg, 81: 69-77.
22. 22. Brown, P.D., R.E. Bloxidge, N.S.A. Stuart, K.C. Gatter & J. Carmichael. 1993. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J. Natl. Cancer Inst. 85: 574-578.
23. 23. Liabakk, N-B., I. Talbot, R.A. Smith, K. Wilkinson & F. Balkwill. 1996. Matrix metalloproteinase 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) Type IV collagenases in colorectal cancer. Cancer Res. 56: 190-196.
24. 24. Hamdy F.C., E.J. Fadlon, D. Cottam, J. Lawry, W. Thurrell, P.B. Silcocks, J.B. Anderson, J.L. Williams & R.C. Rees. 1994. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 69: 177-182.
25. 25. Sier, C.F.M., F.J.G.M. Kubben, S. Ganesh, M.M. Heerding, G. Griffioen, R. Hanemaaijer, J.H. Van Krieken, C.B.H.W. Lamers & H.W. Verspaget. 1996. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 74: 413-417.
26. 26. Hua, J. & R.J. Muschel. 1996. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56: 5279-5284.
27. 27. DeClerck, Y.A., N, Perez, H. Shimada, T.C. Boone, K.E. Langley & S.M. Taylor. 1992. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52: 701-708.
28. 28. Koop, S., R. Khoka, E.E. Schmidt, I.C. MacDonald, V.L. Morris, A.F. Chambers & A.C. Groom. 1994. Overexpression of metalloproteinase inhibitor in B16-f10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54: 4791-4797.
29. 29. Watanabe, M., Y. Takahashi, T. Ohta, M. Mai, T. Sasaki & M. Seiki. 1996. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase I gene in nude mice. Cancer 15: 1676-1680.
30. 30. DeClerck, Y.A., N. Perez, H. Shimada, T.C. Boone, K.E. Langley & S.M. Taylor. 1992. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52: 701-708.
31. 31. Wang, X., X. Fu, P.D. Brown, M.J. Crimmin & R.M. Hoffman. 1994. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54: 4726-4728.
32. 32. Chirivi, R.G., A. Garofalo, M.J. Crimmin, L.J. Bawden, A. Stoppacciaro, P.D. Brown & R. Giavazzi. 1994. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer 58: 460-464.
33. 33. An, Z., X. Wang, N. Willmott, S.K. Chander, S. Tickle, A.J. Docherty, A. Mountain, A.T. Millican, R. Morphy, J.R. Porter, R.O. Epemolu, T. Kubota, A.R. Moossa & R.M. Hoffman. 1997. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin. Exp. Metastasis 15: 184-195.
34. 34. Crawford, H.C. & L.M. Matrisian. 1996. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enyme Protein 49: 20-37.
35. 35. Himelstein, B.P., R. Canete-Soleri, E.J. Bernhard, D.W. Dilks & R. Muschel. 1994. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14: 246-258.
36. 36. Wilson, C.L., K.J. Heppner, P.A. Labosky, B.L. Hogan & L.M. Matrisian. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. 94: 1402-1407.
37. 37. Bender, S.L. 1997. Structure-based design of MMP inhibitors: discovery and development of AG3340. Presented at the 214th National Meeting of the American Chemical Society, Las Vegas, Nevada.
38. 38. Hibner, B., A. Cad, C. Flynn, A.M. Casazza, G. Taraboletti, M. Rieppi & R. Giavazzi. 1998. BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc. Am. Assoc. Cancer Res. 39: 2063.
39. 39. Santos, O., C.D. McDermott, R.G. Daniels & K. Appelt. 1997. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis 15: 499-508.
40. 40. Shalinsky, D.R., J. Brekken, N.V. Varki, S.R. Robinson, R. Daniels, S. Kolis, S. Bansal, H. Zou, S. Bender, S. Zook, S. Margosiak, A.W. Wood, S. Webber & K. Appelt. 1998. Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally-administered AG3340, a novel matrix metalloproteinase inhibitor. Proc. Am. Assoc. Cancer Res. 39: 2059.
41. 41. Shalinsky, D.R., J. Brekken, H. Zou, S. Kolis, A. Wood, S. Webber & K. Appelt. 1999. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest. New Drugs. In press.
42. 42. Shalinsky, D.R., J. Brekken, H. Zou, L. Bloom, C. McDermott, N.M. Varki & K. Appelt. 1999. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human NSCLC tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. In press.
43. 43. Price, A., N.B. Rewcastle, V.W. Yong, Q.S. Zhong. P. Brasher, M.G. Morris, D. Spencer, D. Edwards, K. Appelt & P. Forsyth. 1999. Marked inhibition of tumor growth in a malignant glioma tumor model by the novel, synthetic matrix metalloproteinase (MMP) inhibitor, AG3340. Clin. Cancer Res. 5: 845-854.
44. 44. Shalinsky, D.R., J. Brekken, H. Zou, S. Bender, S. Zook, K. Appelt, S. Webber & N.V. Varki. 1998. Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix metalloproteinase (MMP) inhibitor, AG3340, in male nude mice. Proc. Am. Assoc. Cancer Res. 39: 4400.
45. 45. Neri, A., B. Goggin, S. Kolis, J. Brekken, N. Khelemskaya, L. Gabriel, S.R. Robinson, S. Webber, A.W. Wood, K. Appelt & D.R. Shalinsky. 1998. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in lung after IV-tail implantation in C57BL/6 mice. Proc. Am. Assoc. Cancer Res. 39: 2060.
46. 46. Johnston, M.R., J.B.M. Mullen, M. Pagura, K.A. Appelt & D.R. Shalinsky. 1998. AG3340, a novel matrix metalloproteinase (MMP) inhibitor, inhibits the growth of human large cell lung cancer tumors orthotopically implanted into the lung of athymic nude rats. Proc. Am. Assoc. Cancer Res. 39: A2060.
47. 47. Quinn, L.A., G.E. Moore, R.T. Morgan & L.K, Woods. 1979. Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res. 39: 4914-4924.
48. 48. Kaighn, M.E., K.S. Narayan, Y. Ohnuki, J.F. Lechner & L.W. Jones. 1979. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17: 16-23.
49. 49. Ponten, J. & E.H. Macintyre. 1968. Long term culture of normal and neoplastic human glioma. Acta Pathol. Microbiol. Scand. 74: 465-486.
50. 50. Kelner, M.J., T.C. McMorris, L. Estes, R. Starr, K. Sampson, N. Varki & R. Taetle. 1995. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res. 15: 867-871.
51. 51. Brinkley, B.R., P.T. Beall, L.J. Wible, M.L. Mace, D.S. Turner & R.M. Cailleau. 1980. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129.
52. 52. Cohen, M.B., F.M. Waldman, P.R. Carroll, R. Kerschmann, K. Chew & B.H. Mayhall. 1993. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of urinary bladder. Hum. Pathol. 24: 772-778.
53. 53. Limas, C., A. Bigler, R. Blair, P. Bernhart & P. Reddy. 1993. Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki 67 expression, and nucleolar organiser regions. Clin. Pathol. 46: 159-165.
54. 54. Favaloro, E.J., N. Moraitis, K. Bradstock & J. Koutts. 1990. Co-expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis. Br. J. Haematol. 74: 385-394.
55. 55. Weidner, N. & J. Folkman, 1997. Tumoral vascularity as a prognostic factor in cancer. In Importance Advances in Oncology, V. DeVita, S. Hellman & S.A. Rosenberg, Eds. Lippincott-Raven. Philadelphia.
56. 56. Wijsman, J.H., R.R. Jonker, R. Keizer, C.J.H. Van De Veldes, C.J. Cornelisse & J.H.V. Dierendonck. 1993. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J. Histochem. Cytochem. 41: 7-12.
57. 57. Gehring, M.R., B. Condon, S.A. Margosiak & C.C. Kan. 1995. Characterization of the Phe-81 and Val-82 human fibroblast collagenase catalytic domain purified from Escherichia coli. J. Biol. Chem. 270: 22507.
58. 58. Knight, C.G., F. Willenbrock & G. Murphy. 1992. A novel coumarin-based peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 296: 263-266.
59. 59. Morrison, J.F. 1969. Kinetics of the reversible inhibition of enyzme-catalzyzed reactions by tight binding inhibitors. Biochim. Biophys. Acta 185: 269-286.
60. 60. Yocum, S., L. Lopresti-Morrow, L. Reeves & P. Mitchell. 1999. MMP-13 and MMP-I expression in tissues of normal articular joints. This volume.
61. 61. Chambers, A.F., S. Wylie, I.C. MacDonald, H. Varghese, E.E. Schmidt, V.L. Morris & A.C. Groom. 1998. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16FI melanoma cells. Proc. Am. Assoc. Cancer Res. 39: 566.
62. 62. Flynn, C., C. Bull, D. Eberwein, C. Matherne & B. Hibner. 1998. Anti-metastatic activity of BAY-12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc. Am. Assoc. Cancer Res. 39: 2057.
63. 63. Rivero, M.E., C.R. Garcia, C.D. McDermott, D-U. Bartsch, G. Bergeron-Lynn, K. Zhang, K. Appelt & W.R. Freeman. 1998. Intraocular properties of AG3340, a selective matrix metalloprotease inhibitor with antiangiogenic activity. Invest. Ophthalmol. Visual Sci. 39: S585.
64. 64. Turck, J., A.S. Pollock, L.K. Lee, H.P. Marti & D.H. Lovett. 1996. Matrix metalloprotease 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J. Biol. Chem. 271: 15074-15083.
65. 65. Collier, M.A., G.J, Yuen, S.K. Bansal, S. Kolts, T.G. Chew, K. Appelt & N.J. Clendinin. 1997. A Phase I study of the matrix metalloproteinase inhibitor (MMP) inhibitor, AG3340 given in single doses to healthy volunteers. Proc. Am. Assoc. Cancer Res. 38: A1491.
66. 66. Teicher, B.A., S.A. Holden, G. Ara, E.A. Sotomayor, Z.D. Huang, Y.N. Chen & H. Brem. 1994. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer 57: 920-925.
67. 67. Anderson, I.C., M.A. Shipp, A.J.P. Docherty & B.A. Teicher. 1996. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastatis of murine Lewis lung carcinoma. Cancer Res. 56: 715-720.
68. 68. Mauceri, H.J., N.N. Hanna, M.A. Beckett, D.H. Gorski, M.J. Staba, K.A. Stellato, K. Bigelow, R. Heimann, S. Gately, M. Dhanabal, G.A. Soff, V.P. Sukhatme, D.W. Kufe & R.R. Weichselbaum. 1998. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291.
69. 69. Giavazzi, R., A. Garofalo, C. Ferri, V. Lucchini, E.A. Bone, S. Chiari, P.D. Brown, M.I. Nicoletti & G. Taraboletti. 1998. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of Cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. 4: 985-992.
70. 70. Johnston, M.R., J.M. Mullen, M. Pagura, J. Brekken, H. Zou & D.R. Shalinsky. 1999. AG3340 and carboplatin increase survival in an orthotopic nude rat model of primary and metastatic human lung cancer. Proc. Am. Assoc. Cancer Res. 40: A1046.
71. 71. Perkins, A.S. & D.F. Stern. 1997. Molecular biology of cancer: oncogenes. In Cancer: Principles and Practice of Oncology, 5th ed. V.T. DeVita, S. Hellman & S.A. Rosenberg, Eds. J.B. Lippincott. Philadelphia.
72. 72. Christen, R.D., S. Isonishi, J.A. Jones, A.P. Jekunen, D.K. Hom, R. Kroning, D.P. Gately, F.B. Thiebaut, G. Los & S.B. Howell. 1994. Signaling and drug sensitivity. Cancer Metastasis Rev. 13: 175-189.